ORSERDU Treatment: An Overview for Advanced ER+, HER2- Breast Cancer

ORSERDU (elacestrant) represents a significant advancement in the treatment landscape for a specific subset of breast cancer patients. 


ORSERDU Treatment: An Overview for Advanced ER-Positive, HER2-Negative Breast Cancer

ORSERDU (elacestrant) represents a significant advancement in the treatment landscape for a specific subset of breast cancer patients. As an oral therapy, it offers a targeted approach for individuals living with advanced or metastatic estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, particularly those whose tumors harbor an ESR1 mutation and have progressed following prior endocrine therapy.

What is ORSERDU (Elacestrant)?

ORSERDU is the brand name for elacestrant, an oral selective estrogen receptor degrader (SERD). This class of medication works by targeting the estrogen receptor, a protein found on many breast cancer cells. Estrogen can fuel the growth of ER-positive breast cancers, and endocrine therapies aim to block this pathway.

Unlike some other endocrine therapies, ORSERDU not only blocks the estrogen receptor but also causes its degradation, effectively reducing the number of estrogen receptors available to stimulate cancer cell growth. This dual action is crucial in its mechanism against certain resistant forms of breast cancer.

Indication: Who is ORSERDU For?

ORSERDU is specifically indicated for the treatment of postmenopausal women and adult men with advanced or metastatic ER-positive, HER2-negative breast cancer. However, its use is further refined by a critical biomarker:

Targeted Patient Profile


  • Patients must have ER-positive, HER2-negative advanced or metastatic breast cancer. This means the cancer cells respond to estrogen but do not overexpress the HER2 protein.

  • Their tumors must have an *ESR1* mutation. *ESR1* mutations are common mechanisms by which breast cancer cells develop resistance to standard endocrine therapies.

  • The disease must have progressed following at least one line of endocrine therapy in the metastatic setting.

The identification of an *ESR1* mutation is typically done through a specific diagnostic test, highlighting the importance of personalized medicine in determining eligibility for ORSERDU treatment.

How ORSERDU Works

Estrogen receptors play a pivotal role in the proliferation of ER-positive breast cancer cells. When estrogen binds to these receptors, it triggers signals that promote cell growth and division. Many endocrine therapies aim to interrupt this process by either reducing estrogen levels or blocking the estrogen receptor.

However, *ESR1* mutations can alter the estrogen receptor, making it constitutively active even in the absence of estrogen or in the presence of anti-estrogen drugs. This leads to resistance to many traditional endocrine therapies.

ORSERDU, as a SERD, works by binding to the estrogen receptor in these mutated cells, initiating its degradation. By removing these mutated, overactive receptors, ORSERDU helps to overcome the resistance mechanisms caused by *ESR1* mutations, thereby inhibiting the growth of cancer cells.

Administration and Dosage

ORSERDU is an oral medication, typically taken once daily. It is crucial for patients to follow their healthcare provider's instructions regarding dosage and administration strictly. Adherence to the prescribed regimen is vital for the treatment's effectiveness. Patients should not adjust their dose or discontinue the medication without consulting their doctor.

Potential Side Effects and Considerations

As with any cancer treatment, ORSERDU can be associated with side effects. The profile of side effects can vary among individuals. Before starting treatment, patients should have a thorough discussion with their healthcare team to understand the potential benefits and risks, including common and less common side effects. Your doctor will monitor you closely during treatment and provide guidance on managing any side effects that may occur.

Important Considerations

ORSERDU is a prescription medication and should only be used under the guidance of a qualified healthcare professional experienced in cancer treatment. It represents an important option for patients with a specific type of advanced breast cancer, offering a targeted approach to address resistance mechanisms. While it helps manage the disease, it is not considered a cure. Ongoing research continues to explore its full potential and optimal integration into comprehensive cancer care strategies.